445 completed, 106 terminated, 91 unknown, 28 withdrawn. 388 Phase 2, 226 Phase 1, 99 Phase 3, 26 Not applicable, 12 Phase 4.
Follow Sorafenib: new trials by email Literature Review of Sorafenib trials Research Report on Sorafenib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study Comparing BGB-B2033 With Sorafenib or Lenvatinib in Relapsed Hepatocellular Carcinoma BGB-B2033, Lenvatinib, Sorafenib - Hepatocellular Carcinoma, Liver Cancer | Phase 3 | Not yet recruiting | BeOne Medicines | 492 | 2026-10-01 | 2026-09-23 |
| MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib Gilteritinib, Sorafenib - Acute Myeloid Leukemia (AML), FLT3-ITD Mutation | Phase 3 | Recruiting | The First Affiliated Hospital of Soochow University | 594 | 2026-05-01 | 2026-03-20 |
| Evaluation of the Safety and Efficacy of Mifamurtide Versus Standard Treatment With Sorafenib in Patients With High-risk Osteosarcoma Mifamurtide, Sorafenib - Osteosarcoma | Phase 2 | Recruiting | Anna Raciborska | 40 | 2026-04-01 | 2026-10-07 |
| Efficacy and Safety of Sorafenib in New-Onset Type 1 Diabetes Mellitus Sorafenib, Placebo - Type 1 Diabetes | Phase 2 | Not yet recruiting | Second Xiangya Hospital of Central South University | 10 | 2026-02-01 | 2026-02-12 |
| Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical Study Sorafenib (SORA), Venetoclax (VEN) - Acute Myeloid Leukaemia (AML), Measurable Residual Disease (MRD) | Phase 2 / Phase 3 | Not yet recruiting | Nanfang Hospital, Southern Medical University | 87 | 2025-12-01 | 2025-12-04 |
| A Phase I Study Investigating the Combination of Cladribine, Low Dose Cytarabine and Sorafenib Alternating With Decitabine in Pediatric Relapsed and Refractory Acute Leukemias Cladribine, Cytarabine, Sorafenib - Refractory Acute Leukemia, Relapsed Acute Leukemia | Phase 1 | Withdrawn | M.D. Anderson Cancer Center | 2025-07-31 | 2025-08-06 | |
| Molecular Genetics Guide the Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation Decitabine, Sorafenib (BAY-43-9006)，giritinib, Avastinib - AML, MDS | Phase 2 / Phase 3 | Recruiting | Ruijin Hospital | 126 | 2025-06-10 | 2025-05-18 |
| A Study to Assess the Pharmacokinetics of Sorafenib in Mesoporous Magnesium Carbonate (DPH001) Compared to Nexavar® (sorafenib) in Healthy Volunteers DPH001, Nexavar (Sorafenib) - Healthy | Early Phase 1 | Completed | Disruptive Pharma | 12 | 2025-02-10 | 2025-03-17 |
| AD HOC Trial: Artificial Intelligence-Based Drug Dosing In Hepatocellular Carcinoma Irinotecan, Sonidegib, Sorafenib - Hepatocellular Carcinoma | Phase 2 | Recruiting | University of Florida | 12 | 2024-12-02 | 2026-07-14 |
| A Clinical Study of Sorafenib Combined With Gefitinib for the Treatment of pNET sorafenib, gefitinib - Pancreatic Neuroendocrine Neoplasm, Sorafenib | Unknown | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 20 | 2024-09-30 | 2025-01-10 | |
| Phase 2 Study of WGI-0301 for Advanced HCC WGI-0301 at MTD/RP2D dose IV infusion, QW, WGI-0301 at MTD/RP2D -1 dose IV infusion, QW, Sorafenib 400 mg PO, BID continuously - Advanced Hepatocellular Carcinoma (HCC) | Phase 2 | Recruiting | Zhejiang Haichang Biotech Co., Ltd. | 60 | 2024-07-31 | 2026-09-11 |
| Combination of Toripalimab and JS004 Therapy for ccRCC JS004, Toripalimab, Axitinib - Clear Cell Renal Cell Carcinoma | Phase 2 | Recruiting | Fudan University | 80 | 2024-06-01 | 2024-11-15 |
| Sorafenib Relapase Prophylaxis After HCT With PTBCy Regimen Sorafenib - Acute Myeloid Leukemia, in Relapse, Myelodysplastic Syndromes | Phase 2 | Recruiting | St. Petersburg State Pavlov Medical University | 88 | 2024-05-22 | 2024-08-01 |
| Influence of Sarcopenia in Hepatocellular Carcinoma Patients local ablation, TACE, Sorafenib - Sarcopenia | Unknown | Sohag University | 600 | 2024-02-01 | 2023-12-20 | |
| Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML Homoharringtonine, Cytarabine, Etoposide - AML, Childhood, Acute Myeloid Leukemia | Phase 2 | Recruiting | Children's Hospital of Soochow University | 500 | 2024-01-01 | 2024-08-22 |
| Comparison of the Efficacy and Safety of Venetoclax in Combination With 3 Days Decitabine (DEC3-VEN) vs. Venetoclax in Combination With Azacitidine (VIALE-A) in the Treatment of Elderly Patients or Unfit, New-diagnosis Acute Myeloid Leukemia Patients Experimental: Venetoclax in combination with Decitabine (+-sorafenib), Active Comparator: Standard dose of Venetoclax + Azacitidine - Elderly AML Patients, Unfit, New-diagnosis AML | Phase 3 | Completed | The Second Affiliated Hospital of Kunming Medical University | 154 | 2023-11-01 | 2026-09-09 |
| Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC) Budigalimab, Livmoniplimab, Lenvatinib - Hepatocellular Carcinoma | Phase 2 | Active not recruiting | AbbVie | 130 | 2023-09-21 | 2025-08-14 |
| CXD101 in Immunotherapy-related Liver Cancer Zabadinostat (CXD101) and Geptanolimab, Lenvatinib and Sorafenib - HCC | Phase 2 | Active not recruiting | Stephen Chan Lam | 26 | 2023-08-21 | 2026-06-18 |
| Immunotherapy for Advanced Liver Cancer AlloStim® immunotherapy, FOLFOX regimen, Sorafenib - Hepatocellular Carcinoma | Phase 2 / Phase 3 | Suspended | Mirror Biologics, Inc. | 150 | 2023-08-01 | 2025-10-23 |
| Clinical Pharmacogenetic Study of Sorafenib in Egyptian Patients With Hepatocellular Carcinoma Sorafenib - HCC, Hepatocellular Carcinoma | Phase 1 / Phase 2 | Unknown | Assiut University | 150 | 2023-01-01 | 2024-07-30 |
Showing 20 of 712. Sign in to see all of them.
Carcinoma, Hepatocellular (224) · Carcinoma, Renal Cell (84) · Liver Neoplasms (70) · Neoplasms (53) · Leukemia, Myeloid, Acute (37) · Neoplasm Metastasis (34) · Carcinoma, Non-Small-Cell Lung (33) · Breast Neoplasms (29) · Melanoma (24) · Kidney Neoplasms (22) · Pancreatic Neoplasms (16) · Brain Neoplasms (15) · Recurrence (15) · Lung Neoplasms (14) · Prostatic Neoplasms (14)
National Cancer Institute (NCI) (83) · Bayer (78) · M.D. Anderson Cancer Center (24) · Sun Yat-sen University (20) · Memorial Sloan Kettering Cancer Center (10) · SCRI Development Innovations, LLC (10) · Nanfang Hospital, Southern Medical University (8) · University Health Network, Toronto (8) · Fudan University (7) · St. Jude Children's Research Hospital (7) · Alliance for Clinical Trials in Oncology (6) · H. Lee Moffitt Cancer Center and Research Institute (6) · OHSU Knight Cancer Institute (6) · Pfizer (6) · Yale University (6)
United States (382) · China (126) · Germany (77) · Italy (71) · France (69) · Canada (65) · South Korea (64) · Spain (53) · Taiwan (51) · United Kingdom (49) · Japan (43) · Poland (38) · Belgium (36) · Hong Kong (36) · Russia (34)
Ming Shi, MD (6) · Armando Santoro, MD (3) · Farhad Ravandi-Kashani, MD (3) · George Blumenschein, MD (3) · Giuseppe Procopio, MD (3) · Li Xuan, MD (3) · Qifa Liu (3) · Shukui Qin, MD (3)
PMID 37146227, PMID 37185961, PMID 18650514, PMID 19095497, PMID 27238653, PMID 28410911, PMID 11981766, PMID 12049862, PMID 12540794, PMID 16908937, PMID 23676418, PMID 26361969, PMID 28687477, PMID 30028037, PMID 34052255, PMID 35484400, PMID 36111952, PMID 36852452, PMID 37526095, PMID 39863139, PMID 11981761, PMID 12091661, PMID 14667750, PMID 16557381, PMID 16872361, PMID 16965911, PMID 17189398, PMID 17215530, PMID 17551296, PMID 17625669, PMID 17699864, PMID 17951335, PMID 18056648, PMID 18172272, PMID 18445842, PMID 18477802, PMID 18840822, PMID 19154507, PMID 19171708, PMID 19242495, PMID 19349552, PMID 19451442, PMID 19652055, PMID 19704057, PMID 19739318, PMID 19757215, PMID 19773371, PMID 19806596, PMID 19850637, PMID 20082451
2008 (9), U10CA021115 (8), U10CA032102 (8), 2009 (7), P30CA016672 (7), U10CA031946 (6), 2005 (5), U10CA180821 (5), N01CM62201 (4), N01CM62202 (4), P30CA043703 (4), U10CA025224 (4), U10CA180820 (4), 2004 (3), 2014 (3)